Navigation Links
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
Date:2/17/2009

LONDON, Feb. 17 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria(R) (albiglutide) in men and women with type 2 diabetes. The Phase III programme will include more than 4,000 patients.

"Despite continued advances in diabetes treatment, this devastating disease continues to increase at an alarming pace worldwide. It is clear that new therapies are needed to better control type 2 diabetes and to improve people's lives," said Carlo Russo, MD., Senior Vice President, Biopharm Development, GlaxoSmithKline. "Albiglutide is a novel biological currently being investigated to determine its potential to help people control their blood sugar, particularly when oral treatments alone may not provide an adequate response."

About the Phase III Programme

The Phase III programme for albiglutide will begin with five studies in early 2009. The objective of the programme is to demonstrate durable efficacy and cardiovascular safety of albiglutide as mono- and add-on therapy, in patients with type 2 diabetes. The primary efficacy endpoint for all studies will be the change from baseline in HbA1c compared to placebo and/or active comparators. A majority of the studies will include active comparators, including metformin, sulphonylurea, thiazolidinedione (TZD) insulin and a dipeptidyl peptidase four inhibitor (DPP IV). The study duration is expected to be two to three years and the main dose and regimen for the programme will be 30 mg weekly.

About Albiglutide and Type 2 Diabetes

Albiglutide is an investigational biological, injectable form of human GLP-1 -- a peptide that acts throughout the body to help maintain normal blood-sugar levels and to control appetite. Normally, GLP-1 levels rise during a
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Harbinger Research Initiates Coverage on HearAtLast
7. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
8. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
9. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Liberty University has received accreditation for its resident Clinical ... for Accreditation of Counseling & Related Educational Programs (CACREP). ... & Family Studies , is under the leadership of Dr. ... Behavioral Sciences. Prior to the formation of the new school, ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the ... created for kids with cancer. The Chemo Duck App, available on ... with enjoyable games to help children of all ages living with ... to keep kids entertained, educated and at ease while waiting for ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... help decrease wait time, increase physician productivity,and ... reduce overcrowding,decrease patient wait time, and improve ... endorsed 10 national voluntary consensus standards for,hospital-based ... improve,efficiency and care coordination in emergency departments ...
... out for,the soccer team or training for a dance ... greater than adults. After all, they need,nutrition for growth ... from the foods they consume., Nutritious snacks that ... to,helping young athletes perform at their best. Portable snacks ...
... often must make 2009 plan choices in November, SOUTH ... candidates to choose from at this time of year. For ... usually the,time of the year when they have to choose ... effect in 2009., Many Maine companies offer between two ...
... DALLAS, Oct. 30 Claimsnet.com inc. (OTC,Bulletin Board: CLAI), ... healthcare industry, today reported its,results for the third quarter ... are pleased to report a 27% increase in our ... Claimsnet.,"The increase in overall costs during the third quarter ...
... One errant cough or unexpected,sneeze and the workplace ... As the flu season approaches, HR managers prepare to,deal ... estimates that the cost of influenza to the U.S. ... can range from $71 billion,to $167 billion a year., ...
... VANCOUVER, Oct. 30 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: ... RAMP(R),technology in the 3M(TM) Rapid Detection Flu A+B ... in Washington D.C., officially launching,the RAMP(R) Influenza A/B ... branded,by 3M as the 3M(TM) Rapid Detection Flu ...
Cached Medicine News:Health News:NQF Endorses Measures to Address Care Coordination and Efficiency in Hospital Emergency Departments 2Health News:NQF Endorses Measures to Address Care Coordination and Efficiency in Hospital Emergency Departments 3Health News:Fueling Kids for Sports 2Health News:Health Insurance Open Enrollment Tips 2Health News:Health Insurance Open Enrollment Tips 3Health News:Claimsnet.com Reports Third Quarter 2008 Results 2Health News:Claimsnet.com Reports Third Quarter 2008 Results 3Health News:Going 'Green' May Mean Fewer Colds This Season 2Health News:Going 'Green' May Mean Fewer Colds This Season 3Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 2Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 3Health News:Response Biomedical Announces Launch of RAMP(R) Technology in 3M(TM) Rapid Detection Flu A+B Test at ICAAC/IDSA Conference 4
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: